Sumitomo Chemical is a prominent supplier to the pharmaceutical industry, operating as a Contract Development and Manufacturing Organisation (CDMO). The company offers custom non-GMP and GMP oligonucleotide synthesis capabilities, facilitating the flexible production of small-scale lab samples, ranging from milligrams to large-scale oligonucleotide production in batches varied from several grams to kilograms. Additionally, Sumitomo engages in the manufacture and sale of active pharmaceutical ingredients (APIs) and intermediates sourced from pharmaceutical companies, alongside pharmaceutical chemical products developed in-house, such as generic APIs, bolstered by their advanced organic synthesis technologies and quality assurance capabilities. Moreover, Sumitomo is at the forefront of nucleic acid medicines, which are next-generation pharmaceuticals that utilise oligonucleotides to target the genes and proteins responsible for diseases. The company also undertakes contract manufacturing for oligonucleotide APIs on behalf of pharmaceutical firms.

Services include:
– Custom non-GMP oligonucleotide synthesis
– GMP oligonucleotide synthesis
– Small-scale lab sample production
– Large-scale oligonucleotide production
– Manufacture and sale of APIs and intermediates
– Development of generic APIs
– Contract manufacturing for oligonucleotide APIs